[
  {
    "ts": null,
    "headline": "Zimmer Biomet to Present at the 27th Annual Barclays Healthcare Conference",
    "summary": "Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 27th Annual Barclays Healthcare Conference on Thursday, March 13, 2025, at 9:30 a.m. ET.",
    "url": "https://finnhub.io/api/news?id=193fee02defc8be7f84d2041a262a589345de29acca0fb03753700ae6f25a969",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740745800,
      "headline": "Zimmer Biomet to Present at the 27th Annual Barclays Healthcare Conference",
      "id": 133191094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 27th Annual Barclays Healthcare Conference on Thursday, March 13, 2025, at 9:30 a.m. ET.",
      "url": "https://finnhub.io/api/news?id=193fee02defc8be7f84d2041a262a589345de29acca0fb03753700ae6f25a969"
    }
  },
  {
    "ts": null,
    "headline": "Enovis Continues To Languish Despite Decent Financial Results",
    "summary": "Enovis sees strong growth in its Reconstructive business, but market hesitation persists amid CEO transition and 2025 tariffs. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=92264fc660c5633aa8581963c3d9e160965420b2a23177fd77fa32b9ed0224c0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740731020,
      "headline": "Enovis Continues To Languish Despite Decent Financial Results",
      "id": 132905284,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1460692996/image_1460692996.jpg?io=getty-c-w1536",
      "related": "ZBH",
      "source": "SeekingAlpha",
      "summary": "Enovis sees strong growth in its Reconstructive business, but market hesitation persists amid CEO transition and 2025 tariffs. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=92264fc660c5633aa8581963c3d9e160965420b2a23177fd77fa32b9ed0224c0"
    }
  },
  {
    "ts": null,
    "headline": "John Hancock Disciplined Value Mid Cap Fund Q4 2024 Commentary",
    "summary": "The John Hancock Disciplined Value Mid Cap Fund finished slightly behind the benchmark. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=2f74fd9c9e1c5b7c43a735142cc5e5a6c576ade37166d8f7139ddfaf8414f38f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740730500,
      "headline": "John Hancock Disciplined Value Mid Cap Fund Q4 2024 Commentary",
      "id": 132905210,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442420086/image_1442420086.jpg?io=getty-c-w1536",
      "related": "ZBH",
      "source": "SeekingAlpha",
      "summary": "The John Hancock Disciplined Value Mid Cap Fund finished slightly behind the benchmark. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=2f74fd9c9e1c5b7c43a735142cc5e5a6c576ade37166d8f7139ddfaf8414f38f"
    }
  }
]